

DAFTAR PUSTAKA

1. Agarwal MB. Advances in management of thalassemia (Editorial). *Indian Pediatr*. 2004;114:1457-66.
2. Higgs DR, Thein SL, Woods WG. The molecular pathology of the thalassaemias. In: Weatherall DJ, Clegg B, editors. *The thalassaemia syndromes*. 4th ed. England: Blackwell Science; 2001. p. 133-91.
3. Rund D, Rachmilewitz E. Medical progress: β -thalassemia. *N Engl J Med*. 2005;353:1135-46.
4. Vichinsky E, Levine L. Standards of care guidelines for thalassemia. Oakland: Children's hospital and research center; 2012. p. 1-24.
5. Olivieri NF, Nathan DG, Macmillan JH, Wayne AS, Liu PP, McGee A, et al. Survival in medically treated patients with homozygous β -thalassemia. *N Engl J Med*. 1994;331:574-8.
6. Shamsirasaz AA, Bekheirnia MR, Kamgar M, Pourzahedgilani N, Bouzari N, Habibzadeh M, et al. Metabolic and endocrinologic complications in beta thalassemia major: A multicenter study in Tehran. *BMC Endocrine Disorders*. 2003;3:23-34.
7. DeSanctis V, Skordis N, Soliman A. Endocrine disease. In: Capellini MD, Cohen A, Taher JPA, Viprakasit V, Editors. *Guidelines for the management of transfusion dependent thalassemia (TDT)* 3rd ed. Nicosia: Thalassemia International Federation; 2014. p. 146-56.
8. Tubman VN, Fung EB, Vogiatzi M, Thompson AA, Rogers ZR, Neufeld EJ, et al. Guidelines for the standard monitoring of patients with thalassemia: report of the thalassemia longitudinal cohort. *J Pediatr Hematol Oncol*. 2015;37:162-9.
9. Hashemizadeh H, Noori R. Assessment of hypothyroidism in children with beta-thalassemia major in North Eastern Iran. *Iranian Journal of Pediatric Hematology Oncology*. 2012;2:123-7.
10. Rindang C, Batubara JRL, Amalia P, Satari H. Some aspects of thyroid dysfunction in thalassemia major patients with severe iron overload. *Pediatr Indones*. 2011;51:66-72.
11. Merchant RH, Shirodkar A, Ahmed J. Evaluation of growth, puberty and endocrine dysfunctions in relation to iron overload in multi transfused Indian thalassemia patients. *Indian J Pediatr*. 2011;78:679-83.
12. DeSanctis V. Multicenter study on prevalence of endocrine complications in thalassemia major. *Clinical Endocrinology*. 1995;42:581-6.
13. Zervas A, Katopodi A, Protonotariou A, Livadas S, Karagiorga M, Politis C, et al. Assessment of Thyroid Function in Two Hundred Patients with β -Thalassemia Major. *Thyroid*. 2002;12:3-6.
14. Roth C, Pekrun A, Bartz M, Jarry H, Eber S, Lakomek M, et al. Short stature and failure of pubertal development in thalassaemia major: Evidence for hypothalamic neurosecretory dysfunction of growth hormone secretion and defective pituitary gonadotropin secretion. *Eur J Pediatr*. 1997;156:777-83.
15. Aydinok Y, Darcan S, Plat A, Kavakili K, Nisli G CM et al. Endocrine complications in patients with β -thalassemia major. *J Trop Pediatr* 2002 ; 48 50-54. 2008;

16. Grundy RG, Woods KA, Savage M, Evans JPM. Relationship of endocrinopathy to iron chelation status in young patients with thalassaemia major. *Arch Dis Child*. 1994;71:128–32.
17. Panchal R, Patel A. Prevalence of hypothyroidism in children with thalassaemia- β major in children coming to the New Civil Hospital, Surat, Gujarat. *Int J Med Sci Public Heal*. 2016;5:2475–8.
18. Ratih D, Susanto R, Sudarmanto B. Pengaruh deferasirox terhadap kadar T4 dan TSH pada β -thalassemia mayor dengan kadar ferritin tinggi. *Sari Pediatri*. 2011;12:433-9.
19. Schteingart DE. Gangguan kelenjar tiroid. In: Price SA, Wilson LM, editors. *Patofisiologi: konsep klinis proses-proses penyakit*. 6th ed. Jakarta: Penerbit buku kedokteran EGC; 2003. p. 1225-36.
20. Brook CGD, Brown RS. *Handbook of clinical pediatric endocrinology*. 1st ed. Singapore: Blackwell Publishing; 2008.
21. Creo AL, Schwenk WF. Bone age: A handy tool for pediatric providers. *Pediatrics*. 2017;140:1–11.
22. Styne DM. *Pediatric endocrinology: A clinical handbook*. Switzerland: Springer; 2016.
23. Cunningham MJ, Macklin EA, Neufeld EJ, Cohen AR. Complications of β -thalassaemia major in North America. *Blood*. 2004;104:34-9.
24. Kwiatkowski JL. Hemoglobinopathies. In: Lanzkowsky P, Lipton JM, Fish JD, editors. *Lanzkowsky's manual of pediatric hematology and oncology*. 6th ed. USA: Elsevier; 2016. p. 186-93.
25. Olivieri NF. The β -thalassaemia. *N Engl J Med*. 1999;341:99-109.
26. Vichinsky EP. Changing patterns of thalassaemia worldwide. *Ann N Y Acad Sci*. 2005;1054:18-24.
27. Mengenal thalassaemia [Internet]. Indonesia; 2016 [cited 2018 Jan 03]. Available from: <http://www.idai.or.id/artikel/seputar-kesehatan-anak/mengenal-thalassaemia>.
28. Pootrakul P, Sirankapracha P, Hemsorach S, Mounsub W, Kumbunlue R, Piangitjagum A, et al. A correlations of erythrokinetics, ineffective erythropoiesis, and erythroid precursor apoptosis in Thai patient with thalassaemia. *Blood*. 2000;96:2606-12.
29. Rachmilewitz E, Schrier S. The pathophysiology of β -thalassaemia. In: Steinberg MH, Forget BG, Higgs DR, Nagel RL, editors. *Disorders of hemoglobin: genetics, pathophysiology, and clinical management*. Cambridge, England: Cambridge University Press; 2001. p.233-51.
30. Advani R, Sorenson S, Shinar E, Lande W, Rachmilewitz E, Schrier SL. Characterization and comparison of the red blood cell membrane damage in severe human α - and β -thalassaemia. *Blood*. 1992;79:1058-63.
31. Higgs DR, Thein SL, Wood WG. The pathophysiology of the thalassaemias. In: Weatherall DJ, Clegg B, editors. *The thalassaemia syndromes*. 4th ed. England: Blackwell Science; 2001. p. 192-236.
32. Shinar E, Rachmilewitz EA, Lux SE. Differing erythrocyte membrane skeletal protein defects in alpha and beta thalassaemia. *J Clin Invest*. 1989;83:404-10.
33. Hershko C, Graham G, Bates GW, Rachmilewitz EA. Non-specific serum iron in thalassaemia: an abnormal serum iron fraction of potential toxicity. *Cell Mol Biol*. 2004;50:147-58.

34. Kuypers EA, deJong K. The role of phosphatidylserine in recognition and removal of erythrocytes. *Cell Mol Biol.* 2004;50:147-58.
35. Tavazzi D, Duca L, Graziadei D, Comino A, Fiorelli G, Cappellini MD. Membrane-bound iron contributes to oxidative damage of β -thalassemia intermedia erythrocytes. *Br J Haematol.* 2001;112:48-50.
36. Eldor A, Rachmilewitz EA. The hypercoagulable state in thalassemia. *Blood.* 2022;99:36-43.
37. Centis F, Tabellini L, Lucarelli G, Buffi O, Tonucci P, Persini B, et al. The importance of erythroid expansion in determining the extent of apoptosis in erythroid precursors in patient with β -thalassemia major. *Blood.* 2000;96:3624-9.
38. Mathias LA, Fisher TC, Zeng L, Meiselman HJ, Weinberg KI, Hiti AL, et al. Ineffective erythropoiesis in β -thalassemia major is due to apoptosis at the polychromatophilic normoblast stage. *Exp Haematol.* 2000;28:1343-53.
39. Angelucci E, Bai H, Centis F, Bafti MS, Guido L, Ma L, et al. Enhanced macrophagic attack on β -thalassemia major erythroid precursors. *Haematologica.* 2002;87:578-83.
40. Viprakasit V, Origa R. Genetic basis, pathophysiology and diagnosis. In: Cappellini M, Cohen A, Porter J, Taher A, Viprakasit V, Editors, editors. *Guidelines for the management of transfusion dependent thalassaemia (TDT).* Nicosia: Thalassemia International Federation; 2014. p. 14–25.
41. Galanello R, Origa R. Beta-thalassemia. *Orphanet J Rare Dis.* 2010;5:11:1–15.
42. Olivieri NF, Brittenham GM. Iron-chelating therapy and the treatment of thalassemia. *Blood.* 1997;89:736-61.
43. Borgna-Pignatti C, Galanello R. Thalassemias and related disorders: quantitative disorders of hemoglobin synthesis. *Wintrobe's Clinical Hematology.* 2004;42:1319-65.
44. Porter JB. Practical management of iron overload. *Br J Haematol.* 2001;115:239-52.
45. Rachmilewitz EA, Giardina PJ. How I treat thalassemia. *Blood.* 2011;118:3479-88.
46. Hoffbrand AV, Taher A, Cappellini MD. How I treat transfusional iron overload. *Blood.* 2012;120(3657-3669).
47. Kohgo Y, Ikuta K, Ohtake T, Torimoto Y, Kato J. Body iron metabolism and pathophysiology of iron overload. *Int J Hematol.* 2008;88:7-15.
48. Crichton RR, Wilmet S, Legssyer R, Ward RJ. Molecular and cellular mechanisms of iron homeostasis and toxicity in mammalian cells. *J Inorg Biochem.* 2002;91:9–18.
49. Jacobs A, Beamish MR, Allison M. The measurement of circulating ferritin. *J Clin Pathol.* 1972;25:1003.
50. Jacobs A, Miller F, Worwood M, Beamish MR, Wardrop CA. Ferritin in the serum of normal subjects and patients with iron deficiency and iron overload. *Br Med J.* 1972;4:206–8.
51. Lo SF. Reference intervals for laboratory tests and procedures. In: Kliegman RM, Stanton BF, Geme JWS, Schor NF, Behrman RE, editors. *Nelson textbook of pediatrics.* 20th. Philadelphia: Elsevier; 2011. p. 3464-73.
52. Magro S, Puzzon P, Consarino C, Galati MC, Morgione S, Porcelli D, et al. Hypothyroidism in patients with thalassemia syndromes. *Acta Haematol.*

- 1990;84:72-6.
53. Kurtoglu A, Kurtoglu E, Temizkan AK. Effect of iron overload on endocrinopathies in patients with beta-thalassaemia major and intermedia. *Endokrynol Pol.* 2012;63:260–3.
 54. DeSanctis V, Soliman A, Campisi S, M MY. Thyroid disorders in thalassaemia: An update. *Current Trends in Endocrinology.* 2012;5:17-27.
 55. Asif M, Zahid M, Shaheen U, Kanwal A, Rahman ZU, Hussain Z, et al. Effect of multiple blood transfusions on hormonal profile in thalassemia children. *Rawal Medical Journal.* 2014;39:256-69.
 56. Breuer W, Hershko C, Cabantchik ZI. The importance of nontransferrin bound iron in disorders of iron metabolism. *Transfus Sci.* 2000;23:185-92.
 57. Toumba M, Sergis A, Kanaris C, Skordis N. Endocrine complications in patients with thalassemia major. *Pediatric Endocrinology Reviews.* 2007;5:642-8.
 58. DeSanctis V, Roos M, Gasser T, Fortini M, Raiola G, Galati MC. Italian working group of endocrine complications in non-endocrine diseases. Impact of long-term iron chelation therapy on growth and endocrine functions in thalassemia. *J Pediatr Endocrinol Metab.* 2006;19:471–80.
 59. Angelucci E, Brittenham GM, E MC, Ripalti M, Baronciani D, Giardini C, et al. Hepatic iron concentration and total body iron stores in thalassemia major. *N Engl J Med.* 2000;343:327–31.
 60. De P, Mistry R, Wright C, Pancham S, Burbridge W, Gangopadhyay K, et al. A Review of Endocrine Disorders in Thalassaemia. *Open J Endocr Metab Dis.* 2014;04:25–34.
 61. Rivkees SA. Thyroid disorders in children and adolescents. In: Sperling MA, editor. *Pediatric endocrinology.* 4th ed. Philadelphia: Elsevier; 2015. p. 444-70.
 62. Verburg FA, Hebestreit H, Steigerwald U, Lentjes EGWM, Ergezinger K, Grelle I, et al. Reference ranges for analytes of thyroid function in children. *Horm Metab Res.* 2011;43:422–6.
 63. Lee PA. Disorder of puberty. In: Lifshitz F, editor. *Pediatric Endocrinology.* New York: Marcel Dekker Inc; 1996. p. 179-95.
 64. Sherwood L. Fisiologi manusia dari sel ke sistem. Jakarta. Penerbit buku kedokteran EGC. 2009.
 65. Pulungan AB. Pubertas normal! In: Batubara JRL, Tridjaja B, Pulungan AB, editors. *Buku Ajar Endokrinologi Anak.* 2nd ed. Jakarta: Badan Penerbit Ikatan Dokter Anak Indonesia; 2018. p. 92–101.
 66. Ducharme JR, Forerst MG. Normal pubertal development. In: Bertrand J, Rappaport R, Sizonenko PC, editors. *Pediatric Endocrinology.* 2nd ed. Baltimore: William; 1993. p. 372–86.
 67. Tanner JM. *Foetus into Man.* 2nd ed. England: Castlemead Publication; 1989.
 68. Pramita D, Batubara JRL. Pubertas Terlambat pada Thalassaemia Mayor. *Sari Pediatr.* 2003;5:4–11.
 69. Vogiatzi MG, Macklin EA, Trachtenberg FL, Fung EB, Cheung AM, Vichinski E, et al. Differences in the prevalence of growth, endocrine and vitamin D abnormalities among the various thalassemia syndromes in North America. *Br J Haematol.* 2010;146:546–56.
 70. Pérignon F, Brauner R, Souberbielle JC, de Montalembert M, Girot R. Growth

- and endocrine function in major thalassemia. *Arch Fr Pediatr.* 1993;50:657–63.
71. Moeryono HW, Subroto F, Suryansyah A. Pubertas terlambat pada anak thalassemia di RSAB Harapan Kita Jakarta. 2012;14:162–6.
 72. Thuret I, Pondarré C, Loundou A, Steschenko D, Girot R, Bachir D, et al. Complications and treatment of patients with β -thalassemia in France: results of the national registry. *Haematologica.* 2010;95:724–9.
 73. Halliday JW, Powell LW. Hemochromatosis and other diseases associated with iron overload. In: Lauffer RB, editor. *Iron and Human Disease.* Boca Raton: CRC Press; 1992. p. 132055.
 74. Chern JP, Lin KH, Tsai WY, Wang SC, Lu MY, Lin DT. Hypogonadotropic hypogonadism and hematologic phenotype in patients with transfusion dependent β -thalassemia. *Journal of Pediatric Hematology Oncology.* 2003;25:880-4.
 75. Fung EB, Harmatz PR, Lee PD, Millet M, Bellevue R, Jeng MR, et al. Multi-centre study of iron overload research group. Increased prevalence of iron-overload associated endocrinopathy in thalassemia versus sickle-cell disease. *Br J Haematol.* 2006;135:574–82.
 76. Nicol LE, Allen DB, Czernichow P, Zeitler P. Normal growth and growth disorders. In: Kappy MS, Allen DB, Geffner ME, editors. *Pediatric practice endocrinology.* United States of America: The McGraw-Hill Companies; 2010. p. 23–76.
 77. Grimberg A, Leon DD. Disorders of growth. In: Moshang T, editor. *Pediatric endocrinology: The requisites in pediatrics.* 1st ed. United States of America: Elsevier Mosby; 2005. p. 127–67.
 78. Delvecchio M, Cavallo L. Growth and endocrine function in thalassemia major in childhood and adolescence. *J Endocrinol Invest.* 2010;33:61–8.
 79. De Sanctis V, Elsedfy H, Soliman AT, Zaki Elhakim I, Soliman NA, Elalaily R, et al. Endocrine profile of β -thalassemia major patients followed from childhood to advanced adulthood in a tertiary care center. *Indian J Endocrinol Metab.* 2016;20:454–60.
 80. Made A, Ketut A. Profil pertumbuhan, hemoglobin pre-transfusi, kadar ferritin, dan usia tulang anak pada thalassemia mayor. *Sari Pediatr.* 2016;13:299.
 81. Ghosh S, Bandyopadhyay SK, Bandyopadhyay R, Roy D, Maisnam I, Ghosh MK. A study on endocrine dysfunction in thalassaemia. *J Indian Med Assoc.* 2008;106:655–9.
 82. Fuchs GJ, Tienboon P, Linpisarn S, Nimsakul S, Leelapat P, Tovanabutra S, et al. Nutritional factors and thalassaemia major. *Arch Dis Child.* 1996;74:224–7.
 83. Batubara JRL, Faisal F. Perawakan pendek. In: Batubara JRL, Tridjaja B, Pulungan AB, editors. *Buku ajar endokrinologi anak.* 2nd ed. Jakarta: Badan Penerbit Ikatan Dokter Anak Indonesia; 2018. p. 30–9.
 84. Styne DM. *Pediatric endocrinology: A clinical handbook.* USA: Springer; 2016. 67–72 p.
 85. Greulich W, Pyle I. *Radiographic atlas of skeletal development of the hand and wrist.* 2nd ed. London: Stanford University Press; 1959.
 86. Chirico V, Antonio L, Vincenzo S, Luca N, Valeria F, Basilia P, et al. Thyroid dysfunction in thalassaemic patients: ferritin as a prognostic marker and

- combined iron chelators as an ideal therapy. *Eur J Endocrinol.* 2013;169:785–93.
87. Jaipuria R, R.K. N, Malik R, Shrivastava A, Balani S, Tripathi A. Assessment of thyroid function in children with beta-thalassemia major and its correlation with serum ferritin and transfusion index. *J Evol Med Dent Sci.* 2014;3:847–54.
 88. Porter J, Viprakasit V. Iron overload and chelation. In: Cappellini MD, Cohen AR, Porter J, Taher A, Viprakasit V, Editors., editors. *Guidelines for the management of transfusion dependent thalassaemia (TDT).* 3rd ed. Nicosia: Thalassaemia International Federation; 2014. p. 42–75.
 89. Hoffbrand AV, Cohen A, Hershko C. Role of deferiprone in chelation therapy for transfusional iron overload. *Blood.* 2003;102:17-24.
 90. Piriñçiođlu A euGözü, Deniz T, Gökalp D, Beyazit N, Haspolat K, Söker M. Assessment of thyroid function in children aged 1-13 years with beta-thalassemia major. *Iran J Pediatr.* 2011;21:77–82.
 91. Drema L, Singh P, Singh K, Pannu Ms, Kaur M, Neki Ns. Thyroid profile in multi transfused children of beta thalassemia major and its corelation with serum ferritin levels. *Int J Curr Res Med Sci.* 2017;3:14-21.
 92. Shalitin S, Carmi D, Weintrob N, Phillip M, Miskin H, Kornreich L, et al. Serum ferritin level as a predictor of impaired growth and puberty in thalassemia major patients. *Eur J Haematol.* 2005;74:93–100.
 93. Italian Working Group on Endocrine Complications in Non-Endocrine Disease. Multicenter study on prevalence of endocrine complications in thalassemia major. *Clin Endocrinol* 1995;42:581–6.
 94. Arijanty L, Nasar SS, Madiyono B, Gatot D. Relationships between plasma zinc and ferritin with nutritional status in thalassemic children. *Paediatr Indones.* 2006;46:220–4.

